Tambotatug pelitecan — a potential new second-line treatment option for SCLC

Tambotatug pelitecan, an antibody-drug conjugate directed against B7-H3, shows activity as a second-line option in relapsed small-cell lung cancer (SCLC), a setting in which treatment choices remain very limited and survival after relapse is typically measured in months. The commentary in Nature Reviews Clinical Oncology reviews the trial data supporting this agent and places it alongside other emerging ADCs competing for the post-platinum SCLC space. Confirmation in randomised phase III testing will be required before the drug can be considered a new standard of care.